Food Allergy Science Initiative Receives Landmark Research Grant from National Institute of Allergy and Infectious Diseases to Advance Innovative Neuroimmune Research

BOSTON--(BUSINESS WIRE)--The Food Allergy Science Initiative, Inc. (FASI) is thrilled to announce a prestigious Program Project Grant (P01) from the National Institutes of Health’s, National Institute of Allergy and Infectious Diseases (NIAID) to support a multidisciplinary research program focused on the neuroimmunology of food allergies. FASI will receive $2,339,268 in first-year funding and expects to receive this amount from NIAID annually for five years (a potential maximum of $11.6M), contingent on availability of funds.

The investment will support cutting-edge research led by Program Director, Dr. Ruslan Medzhitov at Yale University, Steven Liberles at Harvard Medical School, and Daniel Mucida at Rockefeller University, continuing their collaboration to uncover fundamental mechanisms by which the nervous and immune systems interact to drive the development and progression of food allergies. The collaboration will also integrate a Bioinformatics Core at Rockefeller University led by Thomas Carroll, Ph.D. and a Transgenic Animal Core led by Brad Lowell, M.D., Ph.D. at the Beth Israel Deaconess Medical Center. Dr. Christine Olsen, M.D., FASI Co-Founder and Executive Chair, will serve as FASI’s PI on the research collaboration.

"It's a tremendous honor to receive this grant from NIAID and to continue to collaborate with the amazing research teams at Harvard Medical School, Rockefeller University and the Beth Israel Deaconess Medical Center to unlock the neuroimmune pathways of food allergies," said FASI's Scientific Founder, Dr. Ruslan Medzhitov.

"This transformative P01 grant, coupled with additional philanthropic investment from FASI’s generous donors, catalyzes a giant leap forward in our understanding of food allergies," said Dr. Carlos Bosques, CEO of FASI. “With the unique expertise of this interdisciplinary team and our effective collaborative model, I’m confident that this work will open the doors to groundbreaking discoveries that will pave the way for the development of transformative therapeutics."

“We’re excited that FASI's cross-disciplinary team characterizing characterize the neuroimmune mechanisms underlying debilitating food allergy conditions is receiving this significant investment. The grant bolsters FASI's collaborative research network and solidifies its leadership position in food allergy research,” added Dr. Christine Olsen of FASI.

The NIAID grant described in this press release is award number P01AI179273. The content of this press release is solely the responsibility of FASI and does not necessarily represent the official views of the National Institutes of Health.